0001209191-23-031634.txt : 20230522 0001209191-23-031634.hdr.sgml : 20230522 20230522214011 ACCESSION NUMBER: 0001209191-23-031634 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230217 FILED AS OF DATE: 20230522 DATE AS OF CHANGE: 20230522 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Yea Christopher CENTRAL INDEX KEY: 0001691102 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-36830 FILM NUMBER: 23946399 MAIL ADDRESS: STREET 1: ONE KENDALL SQUARE, BUILDING 200 STREET 2: SUITE 2203 CITY: CAMBRIDGE STATE: MA ZIP: 02139 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: KalVista Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001348911 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200915291 STATE OF INCORPORATION: DE FISCAL YEAR END: 0430 BUSINESS ADDRESS: STREET 1: 55 CAMBRIDGE PARKWAY STREET 2: SUITE 901E CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (857) 999-0075 MAIL ADDRESS: STREET 1: 55 CAMBRIDGE PARKWAY STREET 2: SUITE 901E CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Therapeutics, Inc. DATE OF NAME CHANGE: 20140916 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Biosurgery, Inc DATE OF NAME CHANGE: 20130102 FORMER COMPANY: FORMER CONFORMED NAME: Carbylan Biosurgery Inc DATE OF NAME CHANGE: 20060105 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0407 4/A 2023-02-17 2023-02-23 0 0001348911 KalVista Pharmaceuticals, Inc. KALV 0001691102 Yea Christopher C/O KALVISTA PHARMACEUTICALS, INC 55 CAMBRIDGE PARKWAY, SUITE 901E CAMBRIDGE MA 02142 0 1 0 0 Chief Development Officer 0 Restricted Stock Unit 2023-02-17 4 M 0 2430 0.00 D Common Stock 2430 26736 D The original Form 4 filed on February 23, 2023, is being amended by this Form 4 amendment solely to correct an administrative error, which mis-reported the vesting schedule and the restricted stock unit as a performance restricted stock unit. Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 17, 2022, subject to continued service through each vesting date. /s/ Benjamin L. Palleiko, Attorney-in-Fact 2023-05-22